近年来,由于治疗方法的改进和完善,急性非淋巴细胞性白血病(ANLL)的疗效已有长足进展,最近Bertino 指出 ANLL 已有10%～15%可以治愈,尽管其治愈率还有待进一步提高,但这毕竟令人鼓舞,其中,关键是早期强烈诱导,争取尽快达到完全缓解(CR)。我们在国际标准 DA 方案的基础上加用三尖杉酯碱组成 HDA 方案强烈化疗,取得较高的 CR 率,现就我院38例 ANLL 临床资料报告如下。 In recent years, due to the improvement and improvement of treatment methods, the efficacy of acute non-lymphocytic leukemia (ANLL) has made considerable progress. Recently, Bertino pointed out that 10% to 15% of ANLL can be cured, although the cure rate still needs to be further improved. But this is encouraging after all. Among them, the key is early strong induction and strive to achieve complete remission (CR) as soon as possible. We added harringtonine to form HDA regimen on the basis of the international standard DA protocol for intensive chemotherapy and achieved a higher CR rate. The clinical data of 38 cases of ANLL in our hospital are reported below.